Malignant pleural mesothelioma: Update, current management, and newer therapeutic strategies

Chest

Volumn 126, Issue 4, 2004, Pages 1318-1329

  Pistolesi, Massimo ^b,c   Rusthoven, James ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF FLORENCE   (Italy)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Chemotherapy; Epidemiology; Gemcitabine; Mesothelioma; Pathogenesis; Pemetrexed; Treatment

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIRUBICIN; ETOPOSIDE; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; INTERLEUKIN 2; IRINOTECAN; METHOTREXATE; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; RANPIRNASE; TALC; TAXANE DERIVATIVE; TETRACYCLINE; VINBLASTINE;

ADVANCED CANCER; BEAM THERAPY; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHROMOSOME ABERRATION; CLINICAL TRIAL; COLON CANCER; CRYSTAL; DECORTICATION; DIARRHEA; DISEASE COURSE; FEBRILE NEUTROPENIA; FRUSTRATION; GENETIC SUSCEPTIBILITY; HUMAN; LEUKOPENIA; LUNG RESECTION; MUSCLE FATIGUE; NEUTROPENIA; NORTH AMERICA; OCCUPATIONAL EXPOSURE; PALLIATIVE THERAPY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; SIMIAN VIRUS 40; THORACOCENTESIS; THORACOSCOPY; THORACOTOMY; TUMOR BIOPSY; WESTERN EUROPE;

EID: 6344248995     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.4.1318     Document Type: Article

References (104)

1. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6:527-535
2. Law MR, Gregor A, Hodson ME, et al. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 1984; 39:255-259
3. Grondin SC, Sugarbaker DJ. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 1999; 116:450S-454S
4. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos in the North Western Cape Province. Br J Industr Med 1960; 17:260-271
5. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145:211-218
6. Connelly RR, Spirtas R, Myers MH, et al. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 1987; 78:1053-1060
7. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999; 79:666-672
8. Doll R. Mortality from lung cancer in asbestos workers. Br J Ind Med 1955; 12:81-86
9. Boutin C, Dumortier P, Rey F, et al. Black spots concentrate asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study. Am J Respir Crit Care Med 1996; 153:444-449
10. Bianchi C, Giarelli L, Grandi G, et al. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997; 6:162-166
11. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med 1982; 96:746-755
12. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980; 46:2736-2740
13. Testa JR, Carbone M, Hirvonen A, et al. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesothelioma. Cancer Res 1998; 58:4505-4509
14. Bocchetta M, Di Resta I, Powers A, et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A 2000; 97:10214-10219
15. Procopio A, Strizzi L, Vianale G, et al. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer 2000; 29:173-179
16. ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 2001; 18:425-433
17. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995; 92:10854-10858
18. Roushdy-Hammady I, Siegel J, Emri S, et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001; 357:444-445
19. Yates DH, Corrin B, Stidolph PN, et al. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 1997; 52:507-512
20. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113:723-731
21. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16:145-152
22. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 1998; 110:397-404
23. Metintas M, Özdemir N, Isikoy S, et al. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. J Comp Assist Tomogr 1995; 19:370-374
24. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients: part 1. Diagnosis. Cancer 1993; 72:389-393
25. Boutin C, Rey F, Viallat J-R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995; 108:754-758
26. Kaiser LR, Bavaria JE. Complications of thoracoscopy. Ann Thorac Surg 1993; 56:796-798
27. Sugarbaker DJ, Richards WG, Garcia JP. Extrapleural pneumonectomy for malignant mesothelioma. Adv Surg 1998; 31:253-271
28. Ho L, Sugarbaker DJ, Skarin AT. Malignant pleural mesothelioma. Cancer Treat Res 2001; 105:327-373
29. King JA, Tucker JA. Evaluation of membranous staining of mesothelioma. Cell Vis 1998; 5:24-27
30. Ordónez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma, Mod Pathol 1998; 11:929-933
31. Ordónez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998; 22:1215-1221
32. Oury TD, Hammar SP, Roggli VL, Ultrastructural features of diffuse malignant mesotheliomas. Hum Pathol 1998; 29:1382-1392
33. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients, Thorax 1976; 31:15-24
34. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108:1122-1128
35. Heelan RT, Rusch VW, Begg CB, et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999; 172:1039-1047
36. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55:731-735
37. Bueno R, Appasani K, Mercer H, et al. The α folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 121:225-233
38. Edwards JG, Faux SP, Plummer SM, et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002; 8:1857-1862
39. Soini Y, Jarvinen K, Kaarteenaho-Wiik R, et al. The expression of P-glycoprotein and multidrug resistance proteins 1 and 1 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 2001; 12:1239-1245
40. Gordon W Jr., Antman KH, Greenberger JS, et al. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 1982; 8:19-25
41. Viallat JR, Rey F, Astoul P, et al. Thoracoscopic talc poudrage pleurodesis for malignant effusions: a review of 360 cases. Chest 1996; 110:1387-1393
42. Middleton GW, Smith IE, O'Brien MER, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998; 9:269-273
43. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117:54-65
44. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122:788-795
45. Vogelzang NJ, Rusthoven J, Symanowski J, et al. A phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644
46. Martinez-Moragón E, Aparico J, Rogado MC, et al. Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J 1997; 10:2380-2383
47. Yim APC, Chan ATC, Lee TW, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996; 62:1655-1658
48. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol 2002; 29:41-50
49. Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994; 12:1156-1163
50. Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997; 9:367-372
51. Rice TW, Adelstein DJ, Kirby TJ, et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1994; 58:24-29
52. Baas P. Chemotherapy for malignant mesothelioma; from doxorubicin to vinorelbine. Semin Oncol 2002; 29:62-69
53. Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983; 52:1981-1985
54. Magri MD, Veronesi A, Foladore S, et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. Tumori 1991; 77:49-51
55. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987; 71:857-858
56. Zidar BL, Green S, Pierce HL, et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 1988; 6:223-226
57. Planting AST, Schellens JHM, Goey SH, et al. Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 1994; 5:373-374
58. Raghavan D, Gianoutsos P, Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990; 8:151-154
59. Harvey VJ, Slevin ML, Ponder BA, et al. Chemotherapy of diffuse malignant mesothelioma: phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984; 54:961-964
60. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study. Br J Cancer 1992; 65:956-960
61. van Meerbeeck J, Debruyne C, van Zandwijk N, et al. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996; 74:961-963
62. Vorobiof DA, Rapoport BL, Chasen MR, et al. Malignant pleural mesothelioma: a phase II trial with docetaxel. Ann Oncol 2002; 13:412-415
63. Steele JPC, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18:3912-3917
64. van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999; 85:2577-2582
65. Andersen MK, Krarup-Hansen A, Martensson G, et al. Ifosfamide in malignant mesothelioma: a phase II study. Lung Cancer 1999; 24:39-43
66. van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur J Cancer 2002; 38:779-783
67. 12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21:1556-1561
68. Baas P, van Meerbeeck J, Groen H, et al. Caelyx™ in malignant mesothelioma: a phase II EORTC study. Ann Oncol 2000; 11:697-700
69. Kosty MP, Herndon JE, Vogelzang NJ, et al. High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study; Cancer and Leukemia Group B 9631. Lung Cancer 2001; 34:289-295
70. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990; 27:239-242
71. Belani CP, Adak S, Aisner S, et al. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group (ECOG 2595) [abstract 1829]. Proc Am Soc Clin Oncol 1999; 18:474a
72. Kindler HL, Belani CP, Herndon JE II, et al. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma: sequential phase II trials by the Cancer and Leukemia Group B. Cancer 1999; 86:1985-1991
73. Kindler HL. Systemic therapy for malignant mesothelioma. American Society of Clinical Oncology 2002 educational book. Orlando, FL: American Society of Clinical Oncology, 38th Annual Meeting, 2002; 359-367
74. Fizazi K, Caliandro R, Soulié P, et al. Combination raltitrexed (Tomudex®)-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer 2000; 36:1514-1521
75. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17:25-30
76. van Haarst JMW, Baas P, Manegold Ch, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86:342-345
77. Schuette W. A phase II trial of gemcitabine/oxaliplatin combination chemotherapy in stage II-IV malignant pleural mesothelioma [abstract 1332]. Proc Am Soc Clin Oncol 2002; 21:334a
78. Steele JPC, Shamash J, Evans MT, et al. Phase II trial of vinorelbine and oxaliplatin ('VO') in malignant pleural mesothelioma (MPM) [abstract 1335]. Proc Am Soc Clin Oncol 2001; 20:335a
79. Halme M, Knuuttila A, Vehmas T, et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 1999; 80: 1781-1785
80. Knuuttila A, Ollikainen T, Halme M, et al. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma: a feasibility study. Anti-Cancer Drugs 2000; 11:257-261
81. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57:1116-1123
82. Adjei AA. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 2000; 11: 1335-1341
83. Calvert H, Bunn PA Jr. Future directions in the development of pemetrexed. Semin Oncol 2002; 29(suppl 5):54-61
84. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1999; 17:1194-1199
85. Spielmann M, Martin M, Namer M, et al. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2001; 2:47-51
86. John W, Picus J, Blanke CD, et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000; 88:1807-1813
87. Hanauske A-R, Chen V, Paoletti P, et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001; 6:363-373
88. Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999; 17:3009-3016
89. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20:3533-3544
90. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1:545-552
91. Calvert H. Folate status and the safety profile of antifolates. Semin Oncol 2002; 29(suppl 5):3-7
92. 12 and folate reduce toxicity of Alimta™ (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite [abstract 300]. Proc Am Soc Clin Oncol 2001; 20:76a
93. Paoletti P, Pistolesi M, Rusthoven JJ, et al. Correlation of pulmonary function tests with best tumor response status: results from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma [abstract 2651]. Proc Am Soc Clin Oncol 2003; 22:659
94. Pistolesi M, Symanowski J, Gatzemeier U, et al. Improving pulmonary function in patients with malignant pleural mesothelioma: results of the phase III trial of pemetrexed + cisplatin vs. cisplatin [abstract P-513]. Lung Cancer 2003; 41(suppl 2):S220
95. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20:274-281
96. Vogelzang N, Taub R, Shin D, et al. Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (Pts) with unresectable malignant Mesothelioma (UMM): analysis of survival [abstract 2274]. Proc Am Soc Clin Oncol 2000; 19:577a
97. Parra HS, Tixi L, Latteri F, et al. Combined regimen of cisplatin, doxorubicin, and α-2b interferon in the treatment of advanced malignant pleural mesothelioma: a phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FON-ICAP).,Cancer 2001; 92:650-656
98. Astoul P, Viallat J-R, Laurent JC, et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993; 103:209-213
99. Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998; 83:2099-2104
100. Imperiale MJ, Pass HI, Sanda MG. Prospects for an SV40 vaccine. Semin Cancer Biol 2001; 11:81-85
101. Nowak AK, Lake RA, Kindler HL, et al. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002; 29:82-96
102. Govindan R, Kratzke RA, Herndon JE, et al. Gefitinib in patients with malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30101) [abstract 2535]. Proc Am Soc Clin Oncol 2003; 22
103. Millward M, Parnis F, Byrne M, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma [abstract 912], Proc Am Soc Clin Oncol 2003; 22
104. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997; 48:628-633